Rocaglamide a

Recombinant mouse TNF (Cat#315–01A) and IL-3 (Cat#213–13) were purchased from Peprotech. FBS (Cat# SH30396) for cell culture medium obtained from HyClone. Rocaglamide A (Cat#HY-19356), SP600125 (Cat#HY-12041) and RSL3 (Cat#HY-100218A) were purchased from MedChemExpress. ISRIB (Cat#SML0843) and tert-Butyl hydroperoxide (t-BuOOH, Cat# 458139) were obtained from Sigma-Aldrich. 4-HNE- (Cat#ab46545) and NRF2- (Cat#16396–1-AP) specific antibodies were purchased from Abcam and ProteinTech, respectively. All the primers and probes used were purchased from Integrated DNA technology (IDT). Middlebrook 7H9 and 7H10 mycobacterial growth media were purchased from BD and prepared according to manufactures instructions.

U937, THP-1, MG63 and 143B cell lines were used in this study. All cell lines were obtained from Cell Bank of Type Culture Collection, Chinese Academy of Science (Shanghai, China) and supplemented with RPMI-1640 containing 10% fetal bovine serum (FBS) (both from Gibco, Grand Island, NY, USA) in 5% CO₂ incubator until 80% confluence. Cells are cultured in a standard humidified incubator at 37 °C in a 5% CO₂ atmosphere. Anakinra (Kineret; Amgen, Thousand Oaks, CA, USA) was used as IL-1β receptor inhibitor and Rocaglamide A (MedChemExpress, New Jersey, USA; Cat.no. HY-19356) was used as NF-κB inhibitor.
Mononuclear cell lines U937 and THP-1 (U937 10 ng/mL; THP-1 100 ng/mL) were induced by phorbol-12-myristate-13-acetate (PMA; MedChemExpress; Cat.no. HY-18739) for three days into macrophages. For induction of M2-TAMs, the cells were cultured in medium with 20 ng/mL interleukin-13 (IL-13) and interleukin-4 (IL-4) for 48 h. After treatment, cells were washed and cultured in serum-free medium for another 24 h.
The ethics committee approval is not required by the local law, as the study involved no human tissues or animals. All cells lines used in this study require no ethics approval.